"The global vaccines market is expected to reach US$56.7 billion
by 2017 with double-digit growth annually."
Of all major vaccines-producing countries, development is highly anticipated from China, fuelled by WHO's March announcement enabling manufacturers to apply for pre-qualifi cations and subsequent eligibility under the UN procurement program. This opens the door to a signifi cant market, driving China vaccines manufacturers to upgrade production to meet stricter quality requirements. Further collaboration with international organizations is predicted, in efforts to strengthen vaccines development.
IBC's 4th Vaccines China 2012 is timely and has been researched with the industry to provide the most comprehensive event focused on vaccines development through to manufacturing. Good manufacturing practices and strategies will be reviewed, alongside potential block-buster technologies and R&D projects. This conference is co-located with the 7th annual China Pharmaceutical R&D Summit and 3rd annual Biosimilars Asia conference to maximize cross-learning, partnering and networking opportunities with biopharma and related industries.
- Registration Open
- Call for Papers
- Call for Speakers
- Receive GTM eblast updates
- Security Code:
- Theme: Forging Successful Collaborations and Ensuring Quality & Compliance
- Contact person: Rita Parasurum
- Event website: http://vaccineschina.com/
- Phone: 6565082401
- Fax: 6565082408